Abstract

Purpose of review. The landscape of biological therapies for allergic diseases is experiencing rapid growth. Food allergy was not the first to be targeted, but the research community has recently begun to recognize the unmet needs in this area. Herein we summarize the state of the art for children experiencing food allergies, with emphasis on the potential scenarios that will open up in the near future.

Recent findings. Over the past decade, several promising strategies have emerged as alternatives to simply eliminating the offending food, which carries the risk of serious adverse reactions. Desensitization via oral immunotherapy has been integrated into clinical practice as a treatment strategy, with the recent inclusion of omalizumab. Furthermore, various delivery methods for immunotherapy, other biologics, small molecules, IGNX001, and PVX108 are being explored.

Summary. The range of accessible therapeutic options for food allergies is expanding; however, significant unmet needs persist. This review aims to provide a concise summary of current and potential therapies for IgE-mediated food allergies and their prospects.

References

  1. NIAID-Sponsored Expert Panel; Boyce JA, Assa’ad A, Burks AW, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol 2010;126(6 Suppl):S1-58. https://doi.org/10.1016/j.jaci.2010.10.007.
  2. Vickery BP, Vereda A, Casale TB, et al. AR101 Oral Immunotherapy for Peanut Allergy. N Engl J Med 2018;379:1991-2001. https://doi.org/10.1056/NEJMoa1812856.
  3. Pajno GB, Fernandez-Rivas M, Arasi S, et al.: EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy 2018;73:799-815. https://doi.org/10.1111/all.13319.
  4. Sicherer SH, Sampson HA. Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. J Allergy Clin Immunol 2018;141:41-58. https://doi.org/10.1016/j.jaci.2017.11.003.
  5. Santos AF, Riggioni C, Agache I, et al. EAACI guidelines on the management of IgE-mediated food allergy. Allergy 2025;80:14-36. https://doi.org/10.1111/all.16345.
  6. Arasi S, Nurmatov U, Dunn-Galvin A, et al. WAO consensus on DEfinition of Food Allergy SEverity (DEFASE). World Allergy Organ J 2023;16:100753. https://doi.org/10.1016/j.waojou.2023.100753.
  7. Arasi S, Fiocchi A. The development of the DEFASE project. Curr Opin Allergy Clin Immunol 2023;23:252-261. https://doi.org/10.1097/ACI.0000000000000904
  8. Arasi S, Lo Scalzo L, Sciannamea M, et al. Use of the DEFASE score in research trials. Curr Opin Allergy Clin Immunol 2025;25:199-204. https://doi.org/10.1097/ACI.0000000000001072.
  9. Gupta R, Mnif T, Reed S, et al. Methodology of the international cross-sectional prevalence and severity study of pediatric and adult IgE-mediated food allergies (ASSESS FA). World Allergy Organ J 2025;18:101105. https://doi.org/10.1016/j.waojou.2025.101105.
  10. Turner PJ, Bognanni A, Arasi S, et al.; World Allergy Organization Consensus on the Use of PAL (ACT-UP!) Working Group. Time to ACT-UP: Update on precautionary allergen labelling (PAL). World Allergy Organ J 2024;17:100972. https://doi.org/10.1016/j.waojou.2024.100972.
  11. Bognanni A, Fiocchi A, Arasi S, et al. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow’s Milk Allergy (DRACMA) guideline update - XII - Recommendations on milk formula supplements with and without probiotics for infants and toddlers with CMA. World Allergy Organ J 2024;17:100888. https://doi.org/10.1016/j.waojou.2024.100888.
  12. Dorris S. Fatal and Near Fatal Anaphylaxis to Food in Children and Young Adults. Immunol Allergy Clin North Am 2025;45:445-455. https://doi.org/10.1016/j.iac.2025.05.001.
  13. Di Bona D, Paoletti G, Ordak M, et al. A 300 IR 5-grass pollen sublingual immunotherapy tablet-specific systematic review and meta-analysis confirms its clinical benefits for patients with allergic rhinoconjunctivitis with or without asthma. World Allergy Organ J 2024;17:100985. https://doi.org/10.1016/j.waojou.2024.100985.
  14. Sato S, Nagakura KI, Yanagida N, et al. Recent Advances in Oral Immunotherapy for Food Allergies. Clin Rev Allergy Immunol 2025;68:89. https://doi.org/10.1007/s12016-025-09108-4
  15. Sehgal S, Starren J, Cattin K, et al. Common data elements for food allergy clinical trials: an overview. Curr Opin Allergy Clin Immunol 2025;25:194-198. https://doi.org/10.1097/ACI.0000000000001075.
  16. Muraro A, Silva D, Halken S, et al.; GA2LEN Food Allergy Guideline Group. Managing food allergy: GA2LEN guideline 2022. World Allergy Organ J 2022;15:100687. https://doi.org/10.1016/j.waojou.2022.100687.
  17. Bégin P, Chan ES, Kim H, et al. CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy. Allergy Asthma Clin Immunol 2020 16:20. https://doi.org/10.1186/s13223-020-0413-7.
  18. Iglesia EGA, Kwan M, Virkud YV, et al. Management of Food Allergies and Food-Related Anaphylaxis. JAMA 2024;331:510-521. https://doi.org/10.1001/jama.2023.26857.
  19. Valluzzi RL, Riccardi C, Urbani S, et al. The baked side: Cow’s milk and egg protein threshold dose distributions in children reacting to baked milk and baked egg. World Allergy Organ J 2024;18:101012. https://doi.org/10.1016/j.waojou.2024.101012
  20. Meyer R, Venter C, Bognanni A, Szajewska H, et al.; WAO DRACMA Guideline Group. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow’s Milk Allergy (DRACMA) Guideline update - VII - Milk elimination and reintroduction in the diagnostic process of cow’s milk allergy. World Allergy Organ J 2023;16:100785. https://doi.org/10.1016/j.waojou.2023.100785.
  21. Athanasopoulou P, Deligianni E, Dean T, et al. Use of baked milk challenges and milk ladders in clinical practice: a worldwide survey of healthcare professionals. Clin Exp Allergy 2017;47:430-434. https://doi.org/10.1111/cea.12890.
  22. Carucci L, Coppola S, Luzzetti A, et al. Immunonutrition for Pediatric Patients with Cow’s Milk Allergy: How Early Interventions Could Impact Long-Term Outcomes. Front Allergy 2021;2:676200. https://doi.org/10.3389/falgy.2021.676200.
  23. de Silva D, Rodríguez Del Río P, de Jong NW, et al.; GA2LEN Food Allergy Guidelines Group. Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: A systematic review and meta-analysis. Allergy 2022;77:1852-1862. https://doi.org/10.1111/all.15211
  24. Jones SM, Burks AW, Keet C, et al. Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. J Allergy Clin Immunol 2016 137:1117-1127.e10. https://doi.org/10.1016/j.jaci.2015.12.1316.
  25. Kidon MI, Shavit R, Levy Y, et al. Peanut oral immunotherapy using an extensively heated and baked novel composition of peanuts. Pediatr Allergy Immunol 2024 35:e14146. https://doi.org/10.1111/pai.14146.
  26. Jones SM, Kim EH, Nadeau KC, et al.; Immune Tolerance Network. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. Lancet 2022;399:359-371. https://doi.org/10.1016/S0140-6736(21)02390-4
  27. Petroni D, Bégin P, Bird JA, et al. Varying Doses of Epicutaneous Immunotherapy with Viaskin Milk vs Placebo in Children with Cow’s Milk Allergy: A Randomized Clinical Trial. JAMA Pediatr 2024 178:345-353. https://doi.org/10.1001/jamapediatrics.2023.6630.
  28. Anagnostou A, Greenhawt M. Epicutaneous immunotherapy: A review of safety and efficacy. Pediatr Allergy Immunol 2025;36:e70096. https://doi.org/10.1111/pai.70096.
  29. de Boissieu D, Dupont C. Sublingual immunotherapy for cow’s milk protein allergy: a preliminary report. Allergy 2006 61:1238-1239. https://doi.org/10.1111/j.1398-9995.2006.01196.x.
  30. Greenhawt M, Sindher SB, Wang J, et al. Phase 3 Trial of Epicutaneous Immunotherapy in toddlers with Peanut Allergy. N Engl J Med 2023;388:1755-1766. https://doi.org/10.1056/NEJMoa2212895.
  31. Petroni D, Bégin P, Bird JA, et al. Varying Doses of Epicutaneous Immunotherapy with Viaskin Milk vs Placebo in Children with Cow’s Milk Allergy: A Randomized Clinical Trial. JAMA Pediatr 2024 178:345-353. https://doi.org/10.1001/jamapediatrics.2023.6630
  32. Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003 348:986-993. https://doi.org/10.1056/NEJMoa022613.
  33. Wood RA, Kim JS, Lindblad R, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol 2016;137:1103-1110.e11. https://doi.org/10.1016/j.jaci.2015.10.005.
  34. MacGinnitie AJ, Rachid R, Gragg H, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol 2017;139:873-881.e8. https://doi.org/10.1016/j.jaci.2016.08.010.
  35. Andorf S, Manohar M, Dominguez T, et al. Observational long-term follow-up study of rapid food oral immunotherapy with omalizumab. Allergy Asthma Clin Immunol 2017;13:51. https://doi.org/10.1186/s13223-017-0223-8.
  36. Zuberbier T, Wood RA, Bindslev-Jensen C, et al. Omalizumab in IgE-Mediated Food Allergy: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract 2023 11:1134-1146. https://doi.org/10.1016/j.jaip.2022.11.036.
  37. Nurmatov UB, Lo Scalzo L, Galletta F, et al. Biologics in IgE-mediated food allergy: A systematic review and meta-analysis of interventional studies. World Allergy Organ J 2025;18:101069. https://doi.org/10.1016/j.waojou.2025.101069.
  38. Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med 2024 390:889-899. https://doi.org/10.1056/NEJMoa2312382.
  39. Arasi S, Cafarotti A, Galletta F, Panetta V, et al. Omalizumab reduces anaphylactic reactions and allows food introduction in food-allergic in children with severe asthma: An observational study. Allergy 2025;80:1074-1085. https://doi.org/10.1111/all.16314.
  40. Fiocchi A, Vickery BP, Wood RA. The use of biologics in food allergy. Clin Exp Allergy 2021;51:1006-1018. https://doi.org/10.1111/cea.13897.
  41. Schuetz JP, Anderson B, Sindher SB. New biologics for food allergy. Curr Opin Allergy Clin Immunol 2024 24:147-152. https://doi.org/10.1097/ACI.0000000000000981.
  42. Azzano P, Paquin M, Langlois A, et al. Determinants of omalizumab dose-related efficacy in oral immunotherapy: Evidence from a cohort of 181 patients. J Allergy Clin Immunol 2021 147:233-243. https://doi.org/10.1016/j.jaci.2020.08.039.
  43. Wood RA, Chinthrajah RS, Eggel A, et al. The rationale for development of ligelizumab in food allergy. World Allergy Organ J 2022 15:100690. https://doi.org/10.1016/j.waojou.2022.100690
  44. https://synapse.patsnap.com/article/novartis-halts-peanut-allergy-trial-for-xolairs-hopeful.
  45. Sindher SB, Nadeau KC, Chinthrajah RS, et al. Efficacy and Safety of Dupilumab in Children with Peanut Allergy: A Multicenter, Open-Label, Phase II Study. Allergy 2025;80:227-237. https://doi.org/10.1111/all.16404.
  46. Chinthrajah RS, Sindher SB, Nadeau KC, et al. Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients with Peanut Allergy. Allergy 2025;80:827-842. https://doi.org/10.1111/all.16420.
  47. Chinthrajah S, Cao S, Liu C, et al. Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy. JCI Insight 2019;4:e131347. https://doi.org/10.1172/jci.insight.131347.
  48. Lin EV, Suresh RV, Dispenza MC. Bruton’s tyrosine kinase inhibition for the treatment of allergic disorders. Ann Allergy Asthma Immunol 2024 133:33-42. https://doi.org/10.1016/j.anai.2024.03.002.
  49. Dispenza MC, Pongracic JA, Singh AM, et al. Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy. J Allergy Clin Immunol 2018 141:1914-1916.e7. https://doi.org/10.1016/j.jaci.2017.12.987.
  50. Wang M, Okamoto M, Domenico J, et al. Inhibition of Pim1 kinase prevents peanut allergy by enhancing Runx3 expression and suppressing T(H)2 and T(H)17 T-cell differentiation. J Allergy Clin Immunol 2012 130:932-944.e12. https://doi.org/10.1016/j.jaci.2012.07.032.
  51. Yamaki K, Yoshino S. Remission of food allergy by the Janus kinase inhibitor ruxolitinib in mice. Int Immunopharmacol 2014;18:217-24. https://doi.org/10.1016/j.intimp.2013.11.029.
  52. Kaul M, End P, Cabanski M, et al. Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clin Transl Sci 2021;14:1756-1768. https://doi.org/10.1111/cts.13005.
  53. Gurel DI, Arasi S. Biologics in the management of IgE-mediated food allergy. What is new? Pediatr Allergy Immunol 2025;36:e70146. https://doi.org/10.1111/pai.70146.
  54. Voskamp AL, Khosa S, Phan T, et al. Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy. Allergy 2024;79:485-498. https://doi.org/10.1111/all.15966.

Downloads

pdf
Authors

Alessandro Fiocchi - Allergy Diseases Research Area, Pediatric Allergology Unit, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy

Vincenzo Fierro - Allergy Diseases Research Area, Pediatric Allergology Unit, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy

Stefania Arasi - Allergy Diseases Research Area, Pediatric Allergology Unit, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy

Arianna Cafarotti - Allergy Diseases Research Area, Pediatric Allergology Unit, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy

Rocco Valluzzi - Allergy Diseases Research Area, Pediatric Allergology Unit, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy

Carmen Mazzuca - Allergy Diseases Research Area, Pediatric Allergology Unit, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy

Lucia Lo Scalzo - Allergy Diseases Research Area, Pediatric Allergology Unit, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy

Sara Urbani - Allergy Diseases Research Area, Pediatric Allergology Unit, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy

Maddalena Sciannamea - Allergy Diseases Research Area, Pediatric Allergology Unit, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy

Maria Vittoria La Toppa - Allergy Diseases Research Area, Pediatric Allergology Unit, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy

Lamia Dahdah - Allergy Diseases Research Area, Pediatric Allergology Unit, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright

Copyright (c) 2026 Italian Journal of Pediatric Allergy and Immunology

How to Cite
Fiocchi, A., Fierro, V., Arasi, S., Cafarotti, A., Valluzzi, R., Mazzuca, C., Lo Scalzo, L., Urbani , S. ., Sciannamea, M. ., La Toppa, M. V. ., & Dahdah, L. (2026). Update on Biologic Therapy in Food Allergy. Italian Journal of Pediatric Allergy and Immunology, 39(4). https://doi.org/10.53151/2531-3916/2025-1752
  • Abstract viewed - 22 times
  • pdf downloaded - 8 times